GLOBUS MEDICAL INC - A (GMED)

Super-investor holdings · 2026 Q2

Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end.

Exited this quarter: Maverick Capital.

All institutions · Form 13F

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 2 sales by 2 insiders ($4.4M).

Source: SEC Form 4 filings, as of Oct 3, 2026. Open-market transactions only.

Politician trading · U.S. House

1 House members reported buying (1 purchases vs 0 sales). Bought by Democrats. Latest buy: Aug 19, 2026.

Source: U.S. House Clerk STOCK Act periodic transaction reports, as of Oct 3, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade. Senate reports are not included yet.

Screens & lenses

Politicians

· Bought by Members — Last 6 months: bought by a U.S. House member

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Lynch PEG — Cheap against its growth rate

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Neff Total Return Ratio — Growth plus dividends divided by P/E is high

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Red Flags

· Earnings Manipulation Suspect (Beneish) — Beneish M-Score above -1.78

Key figures

· Growth — Latest revenue: $2.9B · 5-yr revenue CAGR: 30.1% · Straight growth years: 9

· Graham — Current ratio: 4.26 · Straight profitable years: 16 · Debt ratio: 0.16 · Latest net income: $537.9M

· Lynch PEG — P/E: 19.30 · 5-yr EPS growth: 31.2% · PEG: 0.62

· Cash Flow (FCF) — Latest FCF: $588.8M · FCF yield: 5.7% · Positive FCF years: 3

· Neff Total Return Ratio — EPS growth: 31.2% · Dividend yield: 0.0% · P/E: 19.30 · Neff ratio: 1.61

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 2.81 · Operating cash flow: $753.4M · Net income: $537.9M

· Bought by Members — Members buying: 1 · Buy txns: 1 · Sell txns: 0 · Latest buy: Aug 19, 2026

· Earnings Manipulation Suspect (Beneish) — M-Score: -1.74 · Receivables index: 1.54 · Margin deterioration: 1.14 · Sales growth index: 1.53 · Accruals ratio: -2.4%

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.